KYTXKyverna Therapeutics, Inc.
$6.39-11% 1Y
$6.39
$6.1552 weeks$11.25
Price
-11%1YEnd-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for KYTX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Watch
P/En/a
Market value$375.7M
1 year-11%
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 24, 2026Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis.Regulation FD disclosure · press release
- Aug 11, 2026Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 27, 2026As previously disclosed, on July 22, 2023, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Development and Manufacturing Services Agreement (as amended by Amendment #1 thereto on July 24, 2023, the “Prior Agreement”) with ElevateBio Basecamp, Inc. (“ElevateBio”), pursuant to which ElevateBio has …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry